Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 5/20 | 0.71 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.71 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.71 |
| ▸ | SLCO2A1 | Q92959 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.67 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.67 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.67 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.58 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3364894 | 1.00 | PTGFR (0.71) | PTGFRTBXA2RPTGER2SLCO2A1ALDH1A1 | |
| SCHEMBL11846521 | 1.00 | PTGFR (0.71) | PTGFRTBXA2RPTGER2SLCO2A1ALDH1A1 | |
| SCHEMBL13061506 | 0.99 | PTGFR (0.73) | PTGFRTBXA2RPTGER2SLCO2A1ALDH1A1 | |
| SCHEMBL18656591 | 0.93 | SLCO2A1 (0.70) | PTGFRTBXA2RPTGER2SLCO2A1ALDH1A1 | |
| SCHEMBL19556617 | 0.90 | PTGFR (0.60) | PTGFRTBXA2RPTGER2SLCO2A1ALDH1A1 | |
| SCHEMBL21942140 | 0.88 | PTGFR (0.57) | PTGFRTBXA2RPTGER2SLCO2A1ALDH1A1 | |
| SCHEMBL20069041 | 0.88 | PTGFR (0.58) | PTGFRTBXA2RPTGER2SLCO2A1ALDH1A1 | |
| SCHEMBL17285513 | 0.88 | PTGFR (0.58) | PTGFRTBXA2RPTGER2SLCO2A1ALDH1A1 | |
| SCHEMBL19821586 | 0.87 | PTGFR (0.60) | PTGFRTBXA2RPTGER2SLCO2A1ALDH1A1 | |
| SCHEMBL8902243 | 0.86 | TBXA2R (0.61) | PTGFRTBXA2RPTGER2SLCO2A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897793-B2 | Forming latanoprost; alkylation; reductive desulfurization | INSTYTUT FARMACEUTYCZNY (PL) | 2011-03-01 | — | — | US | claimed |
| US-20080207926-A1 | PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2 ALPHA DERIVATIVES | INSTYTUT FARMACEUTYCZNY (PL) | 2008-08-28 | — | — | US | claimed |
| EP-1891005-A2 | PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2 ALPHA DERIVATIVES | INSTYTUT FARMACEUTYCZNY (PL) | 2008-02-27 | — | — | EP | claimed |
| WO-2006112742-A2 | PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2α DERIVATIVES | INSTYTUT FARMACEUTYCZNY (PL) | 2006-10-26 | — | — | WO | claimed |
| CN-116445419-B | 11dhTxB2 monoclonal antibody, preparation method and application thereof | 北京易安泰生物科技有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116445419-A | 11dhTxB2 monoclonal antibody, preparation method and application thereof | 北京易安泰生物科技有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20180028673-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180028673-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-02-01 | — | — | US | disclosed |
| US-9808531-B2 | Compounds and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170080092-A1 | Compounds And Compositions for the Treatment of Ocular Disorders | Graybug Vision, Inc. (US) | 2017-03-23 | — | — | US | disclosed |
| US-7897793-B2 | Forming latanoprost; alkylation; reductive desulfurization | INSTYTUT FARMACEUTYCZNY (PL) | 2011-03-01 | — | — | US | disclosed |
| US-7897793-B2 | Forming latanoprost; alkylation; reductive desulfurization | INSTYTUT FARMACEUTYCZNY (PL) | 2011-03-01 | — | — | US | disclosed |
| US-20090088473-A1 | METHOD FOR SCREENING OF PROSTAGLANDIN COMPOUNDS COMPRISING AN OPTIMAL FORMULATION FOR THE ENHANCEMENT OF HAIR GROWTH AND THE STIMULATION OF FOLLICULAR ANAGEN AND FORMULATIONS RESULTING THEREFROM | CAYMAN CHEMICAL COMPANY (US) | 2009-04-02 | — | — | US | disclosed |
| US-20080207926-A1 | PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2 ALPHA DERIVATIVES | INSTYTUT FARMACEUTYCZNY (PL) | 2008-08-28 | — | — | US | disclosed |
| US-20080207926-A1 | PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2 ALPHA DERIVATIVES | INSTYTUT FARMACEUTYCZNY (PL) | 2008-08-28 | — | — | US | disclosed |
| EP-1891005-A2 | PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2 ALPHA DERIVATIVES | INSTYTUT FARMACEUTYCZNY (PL) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006112742-A3 | PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2α DERIVATIVES | INST FARMACEUTYCZNY (PL) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006112742-A2 | PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2α DERIVATIVES | INSTYTUT FARMACEUTYCZNY (PL) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006112742-A2 | PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2α DERIVATIVES | INSTYTUT FARMACEUTYCZNY (PL) | 2006-10-26 | — | — | WO | disclosed |
| EP-0628545-A1 | 13,14-Dihydro-PGF2BETA and its isopropyl ester | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028673-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | PTGFR 24/4885TBXA2R 23/4885PTGER2 11/4885 |
| US-20170080092-A1 | Compounds And Compositions for the Treatment of Ocular Disorders | PTGIR, PTGIS, CA2 | PTGFR 24/4885TBXA2R 23/4885PTGER2 11/4885 |
| US-20080207926-A1 | PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2 ALPHA DERIVATIVES | PTGIS, PTGS2, PTGES2 | PTGFR 14/4885TBXA2R 20/4885PTGER2 5/4885 |
| US-20090088473-A1 | METHOD FOR SCREENING OF PROSTAGLANDIN COMPOUNDS COMPRISING AN OPTIMAL FORMULATION FOR THE ENHANCEMENT OF HAIR GROWTH AND THE STIMULATION OF FOLLICULAR ANAGEN AND FORMULATIONS RESULTING THEREFROM | PTGFR, FSHR, FFAR2 | PTGFR 1/4885TBXA2R 283/4885PTGER2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.